Skip to main content
. 2020 Nov 17;60(Suppl 1):S105–S119. doi: 10.1002/jcph.1720

Figure 1.

Figure 1

Impact of PBPK and PK/PD modeling on the preclinical and clinical development of antibody‐drug conjugates. DDI, drug‐drug interaction; ER, exposure‐response analysis; FIH, first in humans; PBPK, physiologically based pharmacokinetics; PopPK, population pharmacokinetics.